MeiraGTx Holdings plc

MGTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-114.2M $-147.8M $-84.0M $-129.6M $-79.6M $-58.0M $-54.7M $-82.9M
Depreciation & Amortization $12.5M $12.8M $13.7M $8.7M $7.9M $4.2M $2.2M —
Depreciation — — — $7.3M $6.3M $3.7M $2.2M $2.1M
Amortization — — — $200.0K $300.0K $20.0K $0 —
Stock-Based Compensation $22.1M $25.2M $27.7M $28.6M $20.8M $18.4M $15.9M $17.9M
Net Cash from Operating Activities $-46.4M $-104.5M $-105.4M $-73.1M $-10.5M $-64.0M $20.0M $-58.9M
Investing Activities
Capital Expenditures $3.8M $5.0M $20.2M $45.0M $46.4M $20.9M $9.0M $11.3M
Business Acquisitions — — — — — — $389.7K —
Net Cash from Investing Activities $-4.1M $23.5M $34.0M $-45.0M $-61.7M $-37.0M $-9.4M $-11.3M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $12.3M $54.5M $84.0M $95.2M $1.7M $82.7M $148.2M $130.0M
Net Change in Cash — — — — — — — —
Free Cash Flow $-50.2M $-109.5M $-125.5M $-118.1M $-56.9M $-84.9M $11.1M $-70.1M
← Newer Page 1 of 2 Older →